3 Persisting problems in tuberculosis

Biomedical Research Reports

Volumn 1, Issue C, 1998, Pages 51-146

  Mckinney, John D ^a   Jacobs Jr , William R ^a   Bloom, Barry R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957073108     PISSN: 18745326     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1874-5326(07)80027-5     Document Type: Article

References (400)

1. Ad Hoc Committee on Health Research Relating to Future Intervention Options. "Investing in Health Research and Development.". (Document TDR/ Gen /96.1) (1996), World Health Organization, Geneva
2. Addington W.W. Patient compliance: The most serious remaining problem in the control of tuberculosis in the United States. Chest 76 Suppl. (1979) 741-743
3. Aebischer T. Recurrent cutaneous leishmaniasis: A role for persistent parasites?. Parasitol. Today 10 (1994) 25-28
4. Afonso L.C.C., Scharton T.M., Vieira L.Q., Wysocka M., Trinchieri G., and Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263 (1994) 235-237
5. Aldovini A., and Young R.A. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature (London) 351 (1991) 479-482
6. Alland D., Kalkut G.E., Moss A.R., McAdam R.A., Hahn J.A., Bosworth W., Drucker E., and Bloom B.R. Transmission of tuberculosis in New York City: An analysis by DNA fingerprinting and conventional epidemiologic methods. N. Engl. J. Med. 330 (1994) 1710-1716
7. American Thoracic Society. Guidelines for short-course chemotherapy. Am. Rev. Respir. Dis. 121 (1980) 611-614
8. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect. Immun. 62 (1994) 2536-2544
9. Armstrong J.A., and Hart P.D. Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J. Exp. Med 134 (1971) 713-740
10. Armstrong J.A., and Hart P.D. Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli: Reversal of the usual fusion pattern and observations on bacterial survival. J. Exp. Med. 142 (1975) 1-16
11. Arno P.S., Murray C.J., Bonuck K.A., and Alcabes P. The economic impact of tuberculosis in hospitals in New York City: A preliminary analysis. J. Law, Med. Ethics 21 (1993) 317-323
12. Aronson J.D., Aronson C.F., and Taylon H.C. A twenty-year appraisal of BCG vaccination in the control of tuberculosis. Arch. Int. Med. 101 (1958) 881-893
13. Auerbach O., Hobby G.L., Small M.J., Lenert T.F., and Comer J.V. The clinicopathologic significance of the demonstration of viable tubercle bacilli in resected lesions. J. Thoracic Surg. 29 (1955) 109-135
14. Azad A.K., Sirakova T.D., Rogers L.M., and Kolattukudy P.E. Targeted replacement of the mycocerosic acid synthase gene in Mycobacterium bovis BCG produces a mutant that lacks mycosides. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 4787-4792
15. Baker S.K., and Glassroth J. Miliary tuberculosis. In: Rom W.N., and Garay S. (Eds). "Tuberculosis" (1994), Little, Brown and Co., Boston, MA. 493-511
16. Balasubramanian V., Wiegeshaus E.H., Taylor B.T., and Smith D.W. Pathogenesis of tuberculosis: Pathway to apical localization. Tubercle Lung Dis. 75 (1994) 168-178
17. Balasubramanian V., Pavelka Jr. M.S., Bardarov S.S., Martin J., Weisbrod T.R., McAdam R.A., Bloom B.R., and Jacobs Jr. W.R. Allelic exchange in Mycobacterium tuberculosis with long linear recombination substrates. J. Bacteriol. 178 (1996) 273-279
18. Banerjee A., Dubnau E., Quemard A., Balasubramanian V., Sun Um K., Wilson T., Collins D., de Lisle G., and Jacobs Jr. W.R. inbA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263 (1994) 227-230
19. Bange F.-C., Brown A.M., and Jacobs Jr. W.R. Leucine auxotrophy restricts growth of Mycobacterium bovis BCG in macrophages. In fec. Immun. 64 (1996) 1794-1799
20. Barnes H.L., and Barnes L.R.P. The duration of life in pulmonary tuberculosis with cavity. Am. Rev. Tuberculosis 18 (1928) 412-424
21. Barnes P.F., Fong S.J., Brennan P.J., Twomey P.E., Mazumder A., and Modlin R.L. Local production of tumor necrosis factor and IFN-γ in tuberculous pleuritis. J. Immunol. 145 (1990) 149-154
22. Barnes P.F., Bloch A.B., Davidson P.T., and Snider D.E. Tuberculosis in patients with human immunodeficiency virus infection. N. Engl. J. Med. 324 (1991) 1644-1650
23. Barnes P.F., Lu S., Abrams J.S., Wang E., Yamamura M., and Modlin R.L. Cytokine production at the site of disease in human tuberculosis. Infect. Immun. 61 (1993) 3482-3489
24. Barnes P.F., Modlin R.L., and Ellner J.J. T-cell responses and cytokines. In: Bloom B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C. 417-435
25. Barnum H.N. Cost savings from alternative treatments for tuberculosis. Soc. Sci. Med. 23 (1986) 847-850
26. Barry III C.E., and Mdluli K. Drug sensitivity and environmental adaptation of mycobacterial cell wall components. Trends Microbiol. 4 (1996) 275-281
27. Bates J.H., and Stead W.W. The history of tuberculosis as a global epidemic. Med. Clin. North Am. 77 (1993) 1205-1217
28. Baulard A., Kremer L., and Locht C. Efficient homologous recombination in fast-growing and slow-growing mycobacteria. J. Bacteriol. 178 (1996) 3091-3098
29. Beck F., and Yegian D. A study of the tubercle bacillus in resected pulmonary lesions. Am. Rev. Tuberculosis 66 (1952) 44-51
30. Beckman E.M., Porcelli S.A., Morita C.T., Behar S.M., Furlong S.T., and Brenner M.B. Recognition of a lipid antigen by CD1-restricted αβ+ T cells. Nature (London) 372 (1994) 691-694
31. Besra G.S., and Chatterjee D. Lipids and carbohydrates of Mycobacterium tuberculosis. In: Bloom B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C. 285-306
32. Black F.L. Measles endemicity in insular populations: Critical community size and its evolutionary implication. J. Theor. Biol. 11 (1966) 207-211
33. Black F.L. Infectious diseases in primitive societies. Science 187 (1975) 515-518
34. Black F.L., Hierholzer W.J., Pinheiro F.D., Evans A.S., Woodall J.P., Opton E.M., Emmons J.E., West B.S., Edsall G., Downs W.G., and Wallace G.D. Evidence for persistence of infectious agents in isolated human populations. Am. J. Epidemiol. 100 (1974) 230-250
35. Blackwell J.M. Genetic susceptibility to leishmanial infections: Studies in mice and man. Parasitology 112 Suppl. (1996) S67-S74
36. Bloch A.B., Cauthen G.M., Onorato I.M., Dansbury K.G., Kelly G.D., Driver C.R., and Snider Jr. D.E. Nationwide survey of drug-resistant tuberculosis in the United States. J. Am. Med. Assoc. 271 (1994) 665-671
37. Bloom B.R., and Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153 (1966) 80-82
38. Bloom B.R., and Fine P.E.M. The BCG experience: Implications for future vaccines against tuberculosis. In: Bloom B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C. 531-557
39. Bloom B.R., and Murray C.J.L. Tuberculosis: Commentary on a reemergent killer. Science 257 (1992) 1055-1064
40. Blower S.M., McLean A.R., Porco T.C., Small P.M., Hopewell P.C., Sanchez M.A., and Moss A.R. The intrinsic transmission dynamics of tuberculosis epidemics. Nature Medicine 1 (1995) 815-821
41. Bobrowitz I.D., and Robins D.E. Ethambutol-isoniazid versus PAS-isoniazid in original treatment of pulmonary tuberculosis. Am. Rev. Respir. Dis. 96 (1967) 428-438
42. Boom W.H., Wallis R.S., and Chervenak K.A. Human Mycobacterium tuberculosis-reactive CD4 + T-cell clones: Heterogeneity in antigen recognition, cytokine production, and cytotoxicity for mononuclear phagocytes. Infect. Immun. 59 (1991) 2737-2743
43. Braun M.M., and Cauthen G. Relationship of the human immunodeficiency virus epidemic to pediatric tuberculosis and Bacillus Calmette Guerin immunization. Pediatr. Infect. Dis. J. 11 (1992) 220-227
44. Brennan P.J., and Draper P. Ultrastructure of Mycobacterium tuberculosis. In: Bloom B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C. 271-284
45. Brewer T.F., and Colditz G.A. Relationship between bacille Calmette-Guerin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Clin. Infect. Dis. 20 (1995) 126-135
46. Brudney K., and Dobkin J. Resurgent tuberculosis in New York City: Human immuno-deficiency virus, homelessness, and the decline of tuberculosis control programs. Am. Rev. Respir. Dis. 144 (1991) 745-749
47. Burlein J.E., Stover K.C., Offutt S., and Hanson M.S. Expression of foreign genes in mycobacteria. In: Bloom B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C. 239-252
48. Buschman E., and Skamene E. Genetic background of the host and expression of natural resistance and acquired immunity to M. tuberculosis. In: Bendinelli M., and Friedman H. (Eds). "Mycobacterium tuberculosis: Interactions with the Immune System" (1988) 59-79 Plenum, New York
49. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am. Rev. Respir. Dis. 92 (1965) 687-703
50. Cantwell M.F., Snider D.E., Cauthen G.M., and Onorato I.M. Epidemiology of tuberculosis in the United States, 1985 through 1992. J. Am. Med. Assoc. 272 (1994) 535-539
51. Cavalli-Sforza L.L., and Cavalli-Sforza F. "The Great Human Diasporas." (1995), Addison-Wesley, New York
52. In: Chamberlayne E.C. (Ed). "Status of Immunization of Tuberculosis in 1971." (1972), U.S. Department of Health, Education, and Welfare, Washington D.C.
53. Chan J., and Kaufmann S.H.E. Immune mechanisms of protection. In: Bloom B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C. 389-415
54. Chan J., Xing Y., Magliozzo R.S., and Bloom B.R. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175 (1992) 1111-1122
55. Chan J., Tanaka K., Carroll D., Flynn J., and Bloom B.R. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect. Immun. 63 (1995) 736-740
56. Chase M.W. The cellular transfer of cutaneous hypersensitivity to tuberculin. Proc. Soc. Exp. Biol. Med. 59 (1945) 134-135
57. Chaulk C.P., Moore-Rice K., Rizzo R., and Chaisson R.E. Eleven years of community-based directly observed therapy for tuberculosis. J. Am. Med. Assoc. 274 (1995) 945-951
58. Clemens D.L. Characterization of the Mycobacterium tuberculosis phagosome. Trends Microbiol. 4 (1996) 113-118
59. Clemens D.L., and Horwitz M.A. Characterization of the Mycobacterium tuberculosis phagosome and evidence that phagosomal maturation is inhibited. J. Exp. Med. 181 (1995) 257-270
60. Cobbett L. The rabbit as a means of distinguishing the human from the bovine type of tuberculosis. J. Patbol. Bacteriol. 35 (1932) 681-699
61. Coetzee A.M., and Berjak J. BCG in the prevention of tuberculosis in an adult population. Proc. Mine Med. Officers Assoc. 48 (1968) 41-53
62. Cohen J. "How Many People Can the Earth Support?" (1995) Norton, New York.
63. Cohn M.L., Oda U., Kovitz C., and Middlebrook G. Studies on isoniazid and tubercle bacilli. I. The isolation of isoniazid-resistant mutants in vitro. Am. Rev. Tuberculosis 70 (1954) 465-475
64. Cohn M.L., Kovitz C., Oda U., and Middlebrook G. Studies on isoniazid and tubercle bacilli. II. The growth requirements, catalase activities, and pathogenic properties of isoniazid-resistant mutants. Am. Rev. Tuberculosis 70 (1954) 641-664
65. Collins D.M. In search of tuberculosis virulence genes. Trends Microbiol. 4 (1996) 426-430
66. Collins D.M., Kawakami R.P., de Lisle G.W., Pascopella L., Bloom B.R., and Jacobs Jr. W.R. Mutation of the principal σ, factor causes loss of virulence in a strain of the Mycobacterium tuberculosis complex. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 8036-8040
67. Colston M.J., and Davis E.O. Homologous recombination, DNA repair, and mycobacterial recA. In: Bloom B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C. 217-226
68. Comroe J.H. Pay dirt: the story of streptomycin. Am. J. Respir. Dis. 117 (1978) 773-781
69. Comstock G.W. Tuberculosis in twins: A re-analysis of the Prophit survey. Am. Rev. Respir. Dis. 117 (1978) 621-624
70. Comstock G.W. Epidemiology of tuberculosis. Am. Rev. Respir. Dis. 125 (1982) 8-16
71. Comstock G.W., and Webster R.G. Tuberculosis studies in Muscogee County, Georgia. VII. A twenty-year evaluation of BCG vaccination in a school population. Am. Rev. Respir. Dis. 100 (1969) 839-845
72. Comstock G.W., Livesay VT., and Woolpert S.F. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am. J. Epidemiol 99 (1974) 131-138
73. Comstock G.W., Livesay V.T., and Woolpert S.F. Evaluation of BCG vaccination among Puerto Rican children. Am. J. Public Health 64 (1974) 283-291
74. Comstock G.W., Woolpert S.F., and Livesay V.T. Tuberculosis studies in Muscogee County, Georgia, Twenty-year evaluation of a community trial of BCG vaccination. Public Health Rep. 91 (1976) 276-280
75. Connell N.D., Medina-Acosta E., McMaster W.R., Bloom B.R., and Russell D.G. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania proteinase gp63. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 11473-11477
76. Cooper A.M., and Flynn J.L. The protective immune response to Mycobacterium tuberculosis. Curr. Opin. Immunol. 7 (1995) 512-516
77. Cooper A.M., Dalton D.K., Stewart T.A., Griffin J.P., Russell D.G., and Orme I.M. Disseminated tuberculosis in interferon γ gene-disrupted mice. J. Exp. Med. 178 (1993) 2243-2247
78. Cooper A.M., Roberts A.D., Rhoades E.R., Callahan J.E., Getzy D.M., and Orme I.M. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 84 (1995) 423-432
79. Corper H.J., and Cohn M.L. The viability and virulence of old cultures of tubercle bacilli: Studies on twelve-year broth cultures maintained at incubator temperature. Am. Rev. Tuberculosis Pulmonary Dis. 28 (1933) 856-874
80. Corper H.J., Lurie M.B., and Uyei N. The variability of localization of tuberculosis in the organs of different animals: III. The importance of the growth of tubercle bacilli as determined by gaseous tension. Am. Rev. Tuberculosis 15 (1927) 65-87
81. Crofton J., and Mitchison D.A. Streptomycin resistance in pulmonary tuberculosis. Br. Med. J. 2 (1948) 1009-1015
82. Crowle A.J., and Elkins N. Relative permissiveness of macrophages from black and white people for virulent tubercle bacilli. Infect. Immun. 58 (1990) 632-638
83. 3 of the multiplication of virulent tubercle bacilli in cultured human macrophages. Infect. Immun. 55 (1987) 2945-2950
84. Dahl K.E., Shiratsuchi H., Hamilton B.D., Ellner J.J., and Toossi Z. Selective induction of transforming growth factor β in human monocytes by lipoarabinomannan of Mycobacterium tuberculosis. Infect. Immun. 64 (1996) 399-405
85. Dahlstrom G. Tuberculosis in BCG vaccinated and non-vaccinated young adults: A comparative prognostic study. Acta Tuberculosea Scand. 32 Suppl. (1952) 1-138
86. Dahlstrom G., and Difs H. The efficacy of BCG vaccination: A study of vaccinated and tuberculin-negative conscripts. Acta Tuberculosea Scand. 27 Suppl. (1951) 1
87. Daniel T.M., Bates J.H., and Downes K.A. History of tuberculosis. In: Bloom B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C. 13-24
88. Dannenberg Jr. A.M., and Rook G.A.W. Pathogenesis of pulmonary tuberculosis: An interplay of tissue-damaging and macrophage-activating immune responses-Dual mechanisms that control bacillary multiplication. In: Bloom B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C. 459-483
89. David J.R. Delayed hypersensitivity in vitro: Its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. U.S.A. 56 (1966) 72-77
90. De Cock K.M., Soro B., Coulibaly I.M., and Lucas S.B. Tuberculosis and HIV infection in sub-Saharan Africa. J. Am. Med. Assoc. 268 (1992) 1581-1587
91. De Cock K.M., Binkin N.J., Zuber P.L.F., Tappero J.W., and Castro K.G. Research issues involving HIV-associated tuberculosis in resource-poor countries. J. Am. Med. Assoc. 276 (1996) 1502-1507
92. De Maio J., Zhang Y., Ko C., Young D.B., and Bishai W.R. A stationary-phase stress-response sigma factor from Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 2790-2794
93. Denis M. Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell. Immunol. 132 (1991) 150-157
94. Denis M. Killing of Mycobacterium tuberculosis within human monocytes: Activation by cytokines and calcitriol. Clin. Exp. Immunol. 84 (1991) 200-206
95. Deretic V., Philipp. W., Dhandayuthapani S., Mudd M.H., Curcic R., Garbe T., Heym B., Via L.E., and Cole S.T. Mycobacterium tuberculosis is a natural mutant with an inactivated oxidative-stress regulatory gene: Implications for sensitivity to isoniazid. Mol. Microbiol. 17 (1995) 889-900
96. Dessen A., Quemard A., Blanchard J.S., Jacobs W.R., and Sacchettini J.C. Crystal structure of the isoniazid target of Mycobacterium tuberculosis. Science 267 (1995) 1638-1641
97. DiMasi J.A. Success rates for new drugs entering clinical testing in the United States. Clin. Pbarmacol. Ther. 58 (1995) 1-14
98. γ. J. Immunol. 145 (1990) 940-944
99. Draper P. The anatomy of mycobacteria. In: Ratledge C., and Stanford J. (Eds). "The Biology of the Mycobacteria", Volume 1: Physiology, Identification and Classification (1982), Academic Press, London 9-52 1982
100. Drolet G.J. The incidence of tuberculous infection among children in New York City: A survey of 14,699 children tuberculin-tested in hospitals or attending clinics, three-year period, 1930-1932. Am. Rev. Tuberculosis 30 (1934) 1-32
101. Drolet G.J. Present trend of case fatality rates in tuberculosis. Am. Rev. Tuberculosis 37 (1938) 125-151
102. Drolet G.J. Epidemiology of tuberculosis. In: Goldberg B. (Ed). "Clinical Tuberculosis" (1946), Davis, Philadelphia A3-A61
103. Dubos R.J. The tubercle bacillus and tuberculosis. Am. Sci. 37 (1949) 353-370
104. Dubos R., and Dubos J. "The White Plague: Tuberculosis, Man, and Society." (1952), Little, Brown and Company, Boston
105. Dubos R.J., and Schaefer W.B. Antituberculous immunity induced in mice by virulent primary infection: Its inhibition by chemoprophylaxis. Am. Rev. Tuberculosis Pulmonary Dis. 74 (1956) 541-551
106. Edwards W.M., Cox Jr. R.S., Cooney J.P., and Crone R.I. Active pulmonary tuberculosis with cavitation of forty-one years' duration. Am. Rev. Respir. Dis. 102 (1970) 448-455
107. Ehrlich P. Address in pathology on chemotherapeutics: Scientific principles, methods, and results. Lancet 2 (1913) 445-451
108. Enarson D.A., and Murray J.F. Global epidemiology of tuberculosis. In: Rom W.N., and Garay S. (Eds). "Tuberculosis" (1996), Little, Brown and Co., Boston, MA. 57-75
109. Engbaek H.C. Growth of Mycobacterium tuberculosis determined by direct agar microscopy. The initial growth of young and old cultures. Acta Patbol. Microbiol. Scand. 31 (1952) 370-376
110. Espersen E. Morphological studies of the normal growth of a human tubercle strain, and the effects of some antibacterial substances on same. Acta Patbol. Microbiol. Scand. 26 (1949) 178-204
111. Everett F.R. The pathological anatomy of pulmonary tuberculosis in the American negro and in the white race. Am. Rev. Tuberculosis 27 (1933) 411-464
112. Ewart W. Pulmonary cavities: Their origin, growth, and repair. Br. Med. J. 1 (1882) 333-337
113. Ewart W. Pulmonary cavities: Their origin, growth, and repair. Br. Med. J. 1 (1882) 369-372
114. Ewart W. Pulmonary cavities: Their origin, growth, and repair. Br. Med. J. 1 (1882) 415-418
115. Ewart W. Pulmonary cavities: Their origin, growth, and repair. Br. Med. J. 1 (1882) 453-456
116. Ewart W. Pulmonary cavities: Their origin, growth, and repair. Br. Med. J. 1 (1882) 493-496
117. Ewart W. Pulmonary cavities: Their origin, growth, and repair. Br. Med. J. 1 (1882) 530-533
118. Ewart W. Pulmonary cavities: Their origin, growth, and repair. Br. Med. J. 1 (1882) 569-572
119. Falk A., Tucker W.B., and Kaufman J.E. A clinical and bacteriologic correlation of resected pulmonary tuberculosis lesions. Am. Rev. Tuberculosis 70 (1954) 689-700
120. Falkinham III J.O., and Crawford J.T. Plasmids. In: Bloom B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C. 185-198
121. Fauci A.S. Host factors and the pathogenesis of HIV-induced disease. Nature (London) 384 (1996) 529-534
122. Feldman W.H. Streptomycin: Some historical aspects of its development as a chemotherapeutic agent in tuberculosis. Am. Rev. Tuberculosis 69 (1954) 859-868
123. Feldman W.H., and Baggenstoss A.H. The residual infectivity of the primary complex of tuberculosis. Am. J. Patbol. 14 (1938) 473-490
124. Feldman W.H., and Baggenstoss A.H. The occurrence of virulent tubercle bacilli in presumably non-tuberculous lung tissue. Am. J. Patbol. 5 (1939) 501-515
125. Ferguson R.G., and Simes A.B. BCG vaccination of indian infants in Saskatchewan. Tubercle 30 (1949) 5-11
126. Filley E.A., and Rook G.A.W. Effect of mycobacteria on sensitivity to the cytotoxic effects of tumor necrosis factor. Infect. Immun. 59 (1991) 2567-2572
127. Filley E.A., Bull H.A., Dowd P.M., and Rook G.A.W. The effect of Mycobacterium tuberculosis on the susceptibility of human cells to the stimulatory and toxic effects of tumour necrosis factor. Immunology 77 (1992) 505-509
128. Fine P.E.M. Immunogenetics of susceptibility to leprosy, tuberculosis, and leishmaniasis. An epidemiological perspective. Int. J. Leprosy 49 (1981) 437-454
129. Fine P.E.M. The BCG story: Lessons from the past and implications for the future. Rev. Infect. Dis. 11 (1989) S353-S359
130. Fine P.E.M., Sterne J.A.C., Ponnighaus J.M., and Rees R.J.W. Delayed-type hyper-sensitivity, mycobacterial vaccines, and protective immunity. Lancet 344 (1994) 1245-1249
131. Finken M., Kirschner P., Meier A., Wrede A., and Bottger E.C. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: Alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol. Microbiol. 9 (1993) 1239-1246
132. Fleming A. On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. influenzae>. Br. J. Exp. Patbol. 10 (1929) 226-236
133. Flesch I.E., and Kaufmann S.H.E. Mycobacterial growth inhibition by interferon-γ-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis. J. Immunol. 138 (1987) 4408-4413
134. Flesch I.E., and Kaufmann S.H.E. Mechanisms involved in mycobacterial growth inhibition by gamma-interferon-activated bone marrow macrophages: Role of reactive nitrogen intermediates. Infect. Immun. 59 (1991) 3213-3218
135. Flesch I.E.A., Hess J.H., Huang S., Aguet M., Rothe J., Bluethmann H., and Kaufmann S.H.E. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon γ and tumor necrosis factor α. J. Exp. Med. 181 (1995) 1615-1621
136. Flynn J.L., Goldstein M.M., Triebold K.J., Koller B., and Bloom B.R. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 12013-12017
137. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., and Bloom B.R. An essential role for interferon y in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178 (1993) 2249-2254
138. Flynn J.L., Goldstein M.M., Triebold K.J., Pfeffer K., Lowenstein C.J., Schreiber R., Mak T.W., and Bloom B.R. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2 (1995) 561-572
139. Flynn J.L., Goldstein M.M., Triebold K.J., Sypek J., Wolf S., and Bloom B.R. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J. Immunol. 155 (1995) 2515-2524
140. Fox W., and Mitchison D.A. Short-course chemotherapy for pulmonary tuberculosis. Am. Rev. Respir. Dis. 111 (1975) 325-353
141. Frieden T.R., Sterling T., Pablos-Mendez A., Kilburn J.O., Cauthen G.M., and Dooley S.W. The emergence of drug-resistant tuberculosis in New York City. N. Engl. J Med. 328 (1993) 521-526
142. Frieden T.R., Fujiwara P.I., Washko R.M., and Hamburg M.A. Tuberculosis in New York City-Turning the tide. N. Engl. J. Med. 333 (1995) 229-233
143. Frimoldt-Moller J., AcharyuLu G.S., and Pillai K.K. Observations on the protective effect of BCG vaccination in a South Indian rural population: Fourth report. Bull. Int. Union Against Tuberculosis 48 (1973) 40-52
144. Frost W.H. The age selection of mortality from tuberculosis in successive decades. Am. J. Hygiene 30 Section A (1939) 91-96
145. Fulton S.A., Johnsen J.M., Wolf S.F., Sieburth D.S., and Boom W.H. Interleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: Role of phagocytosis. Infect. Immun. 64 (1996) 2523-2531
146. Geison G.L. "The Private Science of Louis Pasteur." (1995), Princeton Univ. Press, Princeton, New Jersey
147. Gercken J., Pryjma J., Ernst M., and Flad H.-D. Defective antigen presentation by Mycobacterium tuberculosis-infected monocytes. Infect. Immun. 62 (1994) 3472-3478
148. Ghon A. The primary complex in human tuberculosis and its significance. Am. Rev. Tuberculosis 7 (1923) 314-317
149. Girling D.J. The chemotherapy of tuberculosis. In: Ratledge C., Stanford J., and Grange J.M. (Eds). "The Biology of the Mycobacteria, Volume 3: Clinical Aspects of Mycobacterial Disease" (1989), Academic Press, London 285-323
150. Goble M., Iseman M.D., Madsen L.A., Waite D., Ackerson L., and Horsburgh Jr. C.R. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N. Engl. J. Med. 328 (1993) 527-532
151. Goletti D., Weissman D., Jackson R.W., Graham N.M.H., Vlahov D., Klein R.S., Munsiff S.S., Ortona L., Cauda R., and Fauci A.S. Effect of Mycobacterium tuberculosis on HIV replication: Role of immune activation. J. Immunol. 157 (1996) 1271-1278
152. Goodwin R.A., and Des Prez R.M. Apical localization of pulmonary tuberculosis, chronic pulmonary histoplasmosis, and progressive massive fibrosis of the lung. Chest 83 (1983) 801-805
153. Goren M.B., D'Arcy Hart P., Young M.R., and Armstrong J.A. Prevention of phagosome-lysosome fusion in cultured macrophages by sulfatides of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 73 (1976) 2510-2514
154. Grigg E.R.N. The arcana of tuberculosis, with a brief epidemiologic history of the disease in the U.S.A. Am. Rev. Tuberculosis Pulmonary Dis. 78 (1958) 151-172
155. Grigg E.R.N. The arcana of tuberculosis, with a brief epidemiologic history of the disease in the U.S.A. Am. Rev. Tuberculosis Pulmonary Dis. 78 (1958) 426-453
156. Grigg E.R.N. The arcana of tuberculosis, with a brief epidemiologic history of the disease in the U.S.A. Am. Rev. Tuberculosis Pulmonary Dis. 78 (1958) 583-603
157. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Tubercle 59 (1978) 287-297
158. Guleria I., Teitelbaum R., McAdam R.A., Kalpana G., Jacobs Jr. W.R., and Bloom B.R. Auxotrophic vaccines for tuberculosis. Nat. Med. 2 (1996) 334-337
159. Haas F., and Haas S.S. The origins of Mycobacterium tuberculosis and the notion of its contagiousness. In: Rom W.N., and Garay S. (Eds). "Tuberculosis" (1996), Little Brown Co., Boston, MA. 3-19
160. Hamburg M.A. "Health of the City: Focus on Tuberculosis." (1995), New York City Department of Health, New York
161. Hart P.D. Efficacy and applicability of mass BCG vaccination in tuberculosis control. Br. Med. J. 1 (1967) 587-592
162. Hart P.D., Sutherland I., and Thomas J. The immunity conferred by effective BCG and vole bacillus vaccines, in relation to individual variations in induced tuberculin sensitivity and to technical variations in the vaccines. Tubercle 48 (1967) 201-210
163. Hart P.D., and Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br. Med. J. 2 (1977) 293-295
164. Hatfull G.F., and Jacobs Jr. W.R. Mycobacteriophages: Cornerstones of mycobacterial research. In: Blood B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C.
165. Heinzel F.P., Schoenhaut D.S., Rerko R.M., Rosser L.E., and Gately M.K. Recombinant interleukin 12 cures mice infected with Leisbmania major. J. Exp. Med. 177 (1993) 1505-1509
166. Helweg-Larsen P., Hoffmeyer H., Kieler J., Hess Thaysen E.H., Hess Thaysen J., Thygesen P., and Wulff M.H. Famine disease in German concentration camps: Complications and sequels. Chapter XXI: Tuberculosis. Acta Med. Scand. Supplement 274 (1952) 330-361
167. Heym B., Honore N., Truffot-Pernot C., Bamerjee A., Schurra C., Jacobs Jr. W.R., van Embden J.D.A., Grosset J.H., and Cole S.T. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: A molecular study. Lancet 344 (1994) 293-298
168. Hinshaw H.C. Historical notes on earliest use of streptomycin in clinical tuberculosis. Am. Rev. Tuberculosis 70 (1954) 9-14
169. Hinshaw H.C., Pfuetze K., and Feldman W.H. Treatment of tuberculosis with Promin: A progress report. Am. Rev. Tuberculosis 47 (1943) 26-34
170. Hinshaw H.C., Pfuetze K.H., and Feldman W.H. Chemotherapy of clinical tuberculosis with Promin: p,p'-Diaminodiphenylsulfone-N,N'-didextrose sulfonate; a second report of progress. Am. Rev. Tuberculosis 50 (1944) 52-57
171. 1. J. Infect. Dis. 170 (1994) 1229-1237
172. Hirsch C.S., Hussain R., Toossi Z., Dawood G., Shahid F., and Ellner J.J. Cross-modulation by transforming growth factor β in human tuberculosis: Suppression of antigen-driven blastogenesis and interferon γ production. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 3193-3198
173. Hobby G.L., Auerbach O., Lenert T.F., Small M.J., and Comer J.V. The late emergence of M. tuberculosis in liquid cultures of pulmonary lesions resected from humans. Am. Rev. Tuberculosis 70 (1954) 191-218
174. Hobby G.L., and Lenert T.F. The in vitro of antituberculous agents against multiplying and non-multiplying microbial cells. Am. Rev. Tuberculosis 76 (1957) 1031-1048
175. Hoge C.W., Fisher L., Donnell Jr. H.D., Dodson D.R., Tomlinson Jr. G.V., Breiman R.F., Bloch A.B., and Good R.C. Risk factors for transmission of Mycobacterium tuberculosis in a primary school outbreak: Lack of racial difference in susceptibility to infection. Am. J. Epidemiol. 139 (1994) 520-530
176. Honda M., Matsuo K., Nakasone T., Okamoto Y., Yoshizaki H., Kitamura K., Sugiura W., Watanabe K., Fukushima Y., Haga S., Katsura Y., Tasaka H., Komuro K., Yamada T., Asano T., Yamazaki A., and Yamazaki S. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 10693-10697
177. Honore N., and Cole S.T. Streptomycin resistance in mycobacteria. Antimicrobial Agents Cbemother. 38 (1994) 238-242
178. Horwitz M.A., Lee B.-W.E., Dillon B.J., and Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 1530-1534
179. Hsu H.S. In vitro studies on the interactions between macrophages of rabbits and tubercle bacilli. I. Cellular basis of native resistance. Am. Rev. Respir. Dis. 91 (1965) 488-498
180. Hsu H.S. In vitro studies on the interactions between macrophages of rabbits and tubercle bacilli. II. Cellular and humoral aspects of acquired resistance. Am. Rev. Respir. Dis. 91 (1965) 499-509
181. Huygen K., Content J., Denis O., Montgomery D.L., Yawman A.M., Deck R.R., DeWitt C.M., Orme I.M., Baldwin S., D'Souza C., Drowart A., Lozes E., Vandenbussche P., van Vooren J.-P., Liu M.A., and Ulmer J.B. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat. Med. 2 (1996) 893-898
182. Institute of Medicine. "America's Vital Interest in Global Health: Protecting our People, Promoting Economic Interests, and Projecting U. S. Influence Abroad." (1997), National Academy Press, Washington D.C.
183. Iseman M.D. Treatment of multidrug-resistant tuberculosis. N. Engl. J. Med. 329 (1993) 784-791
184. Iseman M.D., Cohn D.L., and Sharbaro J.A. Directly observed treatment of tuberculosis: We can′t afford not to try it. N. Engl. J. Med. 328 (1993) 576-578
185. Ivanyi J., and Thole J. Specificity and function of T- and B-cell recognition in tuberculosis. In: Bloom B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C. 437-458
186. Johansen K.A., Gill R.E., and Vasil M.L. Biochemical and molecular analysis of phospholipase C and phospholipase D activity in mycobacteria. Infect. Immun. 64 (1996) 3259-3266
187. Johnson B.J., and McMurray D.N. Cytokine gene expression by cultures of human lymphocytes with autologous Mycobacterium tuberculosis-infected monocytes. Infect. Immun. 62 (1994) 1444-1450
188. Jones G.S., Amirault H.J., and Anderson B.R. Killing of Mycobacterium tuberculosis by neutrophils: a nonoxidative process. J. Infect. Dis. 162 (1990) 700-704
189. Jouanguy E., Altare F., Lamhamedi S., Revy P., Emile J.-F., Newport M., Levin M., Blanche S., Fischer A., and Casanova J.-L. Interferon-γ-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N. Engl. J. Med. 335 (1996) 1956-1961
190. Kahn M.C. A developmental cycle of the tubercle bacillus as revealed by single-cell studies. Am. Rev. Tuberculosis 20 (1929) 150-200
191. Kallmann F.J., and Reisner D. Twin studies on the significance of genetic factors in tuberculosis. Am. Rev. Tuberculosis 47 (1943) 549-574
192. Kanai K., and Yanagisawa K. Antibacterial action of streptomycin against tubercle bacilli of various growth phase. Japan J. Med. Sci. Biol. 8 (1955) 63-76
193. Kanai K. Experimental studies on host-parasite equilibrium in tuberculous infection, in relation to vaccination and chemotherapy. Japan J. Med. Sci. Biol. 19 (1966) 181-199
194. Kanai K., and Kondo E. Limits in tuberculosis chemotherapy as revealed by experimental studies in mice. Japan J. Med. Sci. Biol. 24 (1971) 313-321
195. Kapur V., Whittam T.S., and Musser J.M. Is Mycobacterium tuberculosis 15,000 years old? J. Infect. Dis. 170 (1994) 1348-1349
196. Kapur V., Li L.L., Iordanescu S., Hamrick M.R., Wanger A., Kreiswirth B.N., and Musser J.M. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase β subunit in rifampicin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J. Clin. Microbiol. 32 (1994) 1095-1098
197. Karlson A.G., Pfuetze K.H., Carr D.T., Feldman W.H., and Hinshaw C.H. The effect of combined therapy with streptomycin, para-aminosalicylic acid, and promin on the emergence of streptomycin-resistant strains of tubercle bacilli: a preliminary report. Proc. Staff Meet. Mayo Clinic 24 (1949) 85-88
198. Kasahara K., Tobe T., Tomita M., Mukaida N., Shao-Bo S., Matsushima K., Yoshida T., Sugihara S., and Kobayashi K. Selective expression of monocyte chemotactic and activating factor/monocyte chemoattractant protein 1 in human blood monocytes by Mycobacterium tuberculosis. J. Infect. Dis. 170 (1994) 1238-1247
199. Keeling M.J., and Grenfell B.T. Disease extinction and community size: Modeling the persistence of measles. Science 275 (1997) 65-67
200. Kempner W. Oxygen tension and the tubercle bacillus. Am. Rev. Tuberculosis 40 (1939) 157-168
201. Kereszturi C., Park W.H., and Logie A.J. A study of 2,900 chest roentgenograms of BCG vaccinated and control infants in tuberculous families. Trans. Natl. Tuberculosis Assoc. 97 (1935) 97-108
202. King C., Sahish M., Crawford J.T., and Shinnick T.M. Expression of contact-dependent cytolytic activity of Mycobacterium tuberculosis and isolation of the locus encoding the activity. Infect. Immun. 61 (1993) 2708-2712
203. Koch R. Die Aetiologie der Tuberkulose. Ber. Klin. Wocbenscbrift 15 (1882)
204. Koch R. The aetiology of tuberculosis. Am. Rev. Tuberculosis 25 (1932) 298-323
205. Kopanoff D.E., Snider D.E., and Johnson M. Recurrent tuberculosis: Why do patients develop disease again? Am. J. Public Health 78 (1988) 30-33
206. Krause A.K. Introduction to the aetiology of tuberculosis (translated from the German). Am. Rev. Tuberculosis 25 (1932) 285-298
207. Kudoh S. The growth mode of mycobacterium under microculture. Acta Tuberculosea Scand. 32 (1956) 74-87
208. Kumararatne D.S., Pithie A.S., Drysdale P., Gaston J.S.H., Kiessling R., Iles P.B., Ellis C.J., Innes J., and Wise R. Specific lysis of mycobacterial antigen-bearing macrophages by class II MHC-restricted polyclonal T cell lines in healthy donors or patients with tuberculosis. Clin. Exp. Immunol. 80 (1990) 314-323
209. Lancet. Professor Koch′s remedy for tuberculosis. Lancet 2 (1890) 1118-1122
210. Lancet. Professor Koch′s remedy for tuberculosis. Lancet 2 (1890) 1239-11143
211. Lancet. Professor Koch′s remedy for tuberculosis. Lancet 2 (1890) 1282
212. Lancet. Professor Koch′s remedy for tuberculosis. Lancet 2 (1890) 1290-1296
213. Lancet. Professor Koch′s remedy for tuberculosis. Lancet 2 (1890) 1347-1352
214. Lancet. Control of tuberculosis. Lancet 2 (1949) 1225
215. Langermann S., Palaszynski S., Sadziene A., Stover C.K., and Koenig S. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature (London) 372 (1994) 552-555
216. Laochumroonvorapong P., Wang J., Chau-Ching L., Ye W., Moreira A.L., Elkon K.B., Freedman V.H., and Kaplan G. Perforin, a cytotoxic molecule which mediates cell necrosis, is not required for the early control of mycobacterial infection in mice. Infect. Immun. 65 (1997) 127-132
217. Leao S.C., Rocha C.L., Murillo L.A., Parra C.A., and Patarroyo M.E. A species-specific nucleotide sequence of Mycobacterium tuberculosis encodes a protein that exhibits hemolytic activity when expressed in Escherichia coli. Infect. Immun. 63 (1995) 4301-4306
218. Lin Y., Zhang M., Hofman F.M., Gong J., and Barnes P.F. Absence of a prominent Th2 cytokine response in human tuberculosis. Infect. Immun. 64 (1996) 1351-1356
219. Lindgren I. Anatomical and roentgenologic studies of tuberculous infections in BCG-vaccinated and non-vaccinated subjects. Acta Radiologica Supplement 209 (1961) 7-101
220. Lindgren I. The pathology of tuberculous infection in BCG-vaccinated humans. Ad. Tuberculosis Res. 14 (1965) 202-234
221. Lister J. Lecture on Koch′s treatment of tuberculosis. Lancet 2 (1890) 1257-1259
222. Loebel R.O., Shorr E., and Richardson H.B. The influence of adverse conditions upon the respiratory metabolism and growth of human tubercle bacilli. J. Bacteriol. 26 (1933) 167-200
223. Lorgat F., Keraan M.M., Lukey P.T., and Ress S.R. Evidence for in vivo generation of cytotoxic T cells: PPD-stimulated lymphocytes from tuberculous pleural effucions demonstrate enhanced cytotoxicity with accelerated kinetics of induction. Am. Rev. Respir. Dis. 145 (1992) 418-423
224. Lucas S., and Nelson A.M. Pathogenesis of tuberculosis in human immunodeficiency virus-infected people. In: Blood B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C. 503-513
225. Lurie M. "Resistance to Tuberculosis: Experimental Studies in Native and Acquired Defensive Mechanisms." (1964), Harvard Univ. Press, Cambridge, Massachusetts
226. McAdam R.A., Guilhot C., and Gicquel B. Transposition in mycobacteria. In: Bloom B.B. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C. 199-216
227. McAdam R.A., Weisbrod T.R., Martin J., Scuderi J.D., Brown A.M., Cirillo J.D., Bloom B.R., and Jacobs Jr. W.R. In vivo growth characteristics of leucine and methionine auxotrophic mutants of Mycobacterium bovis BCG generated by transposon mutagenesis. Infect. Immun. 63 (1995) 1004-1012
228. McCune R.M., and Tompsett R. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J. Exp. Med. 104 (1956) 737-762
229. McCune R.M., Tompsett R., and McDermott W. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J. Exp. Med. 104 (1956) 763-801
230. McCune R.M., Feldmann F.M., Lambert H.P., and McDermott W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med. 123 (1966) 445-468
231. McCune R.M., Feldmann F.M., and McDermott W. Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli. J. Exp. Med. 123 (1966) 469-486
232. McDermott W. The story of INH. J. Infect. Dis. 119 (1969) 678-683
233. McDermott W., McCune Jr. R.M., and Tompsett R. Dynamics of antituberculous chemotherapy. Am. Rev. Tuberculosis Pulmonary Dis. 74 Suppl. (1956) S100-S108
234. McDonough K.A., and Kress Y. Cyotoxicity for lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis. Infect. Immun. 63 (1995) 4802-4811
235. McDonough K.A., Kress Y., and Bloom B.R. Pathogenesis of tuberculosis: Interaction of Mycobacterium tuberculosis with macrophages. Infect Immun. 61 (1993) 2763-2773
236. McFadden J. Recombination in mycobacteria. Mol. Microbiol. 21 (1996) 205-211
237. McGrath J.W. Social networks of disease spread in the Lower Illinois Valley: A simulation approach. Am. J. Pbys. Antbropol. 77 (1988) 483-496
238. Mackaness G.B., and Blanden R.V. Cellular immunity. Prog. Allergy 11 (1967) 89-140
239. McNeil M.R., and Brennan P.J. Structure, function and biogenesis of the cell envelope of mycobacteria in relation to bacterial physiology, pathogenesis and drug resistance; some thoughts and possibilities arising from recent structural information. Res. Microbiol. 142 (1991) 451-464
240. McNeill W.H. "Plagues and Peoples." (1976), Doubleday, New York
241. McNeill W.H. "The Global Condition." (1992), Princeton Univ. Press, Princeton, New Jersey
242. Mazzaccaro R.J., Gedde M., Jensen E.R., van Santen H.M., Ploegh H.L., Rock K.L., and Bloom B.R. Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 11786-11791
243. Medina E., and North R.J. Evidence inconsistent with a role for the Bcg gene (Nramp 1) in resistance of mice to infection with virulent Mycobacterium tuberculosis. J. Exp. Med. 183 (1996) 1045-1051
244. Medlar E.M. Pulmonary tuberculosis in cattle: The location and type of lesions in naturally acquired tuberculosis. Am. Rev. Tuberculosis 41 (1940) 283-306
245. Medlar E.M. The pathogenesis of minimal pulmonary tuberculosis: A study of 1,225 necropsies in cases of unexpected and sudden death. Am. Rev. Tuberculosis 58 (1948) 583-611
246. Medlar E.M., and Sasano K.T. A study of the pathology of experimental pulmonary tuberculosis in the rabbit. Am. Rev. Tuberculosis 34 (1936) 456-476
247. Meylan P.R.A., Richman D.D., and Kornbluth R.S. Reduced intracellular growth of mycobacteria in human macrophages cultivated at physiologic oxygen pressure. Am. Rev. Respir. Dis. 145 (1992) 947-953
248. Middlebrook G. Isoniazid-resistance and catalase activity of tubercle bacilli. Am. Rev. Tuberculosis 69 (1954) 471-472
249. Middlebrook G., Cohn M.L., and Schaefer W.B. Studies on isoniazid and tubercle bacilli. III. The isolation, drug-susceptibility, and catalase-testing of tubercle bacilli from isoniazid-treated patients. Am. Rev. Tuberculosis 70 (1954) 852-872
250. Middlebrook G., and Yegian D. Certain effects of streptomycin on mycobacteria in vitro. Am. Rev. Tuberculosis 54 (1946) 553-558
251. Mitchison D.A., and Selkon J.B. The bactericidal activities of antituberculous drugs. Am. Rev. Tuberculosis Pulmonary Dis. 74 Suppl. (1956) S109-S123
252. Molloy A., Laochumroovorapong P., and Kaplan G. Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guerin. J. Exp. Med. 180 (1994) 1499-1509
253. Moreno C., Taverne J., Mehlert A., Bate C.A.W., Brealey R.J., Meager A., Rook G.A.W., and Playfair J.H.L. Lipoarabinomannan from Mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages. Clin. and Exp. Immunol. 76 (1989) 240-245
254. MRC. Treatment of pulmonary tuberculosis with para-aminosalicylic acid and streptomycin. Br. Med. J. 2 (1949) 1521
255. MRC. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescents: First report to the Medical Research Council by their tuberculosis vaccines clinical trials committee. Br. Med. J. 1 (1956) 413-427
256. MRC. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescents: Second report to the Medical Research Council by their tuberculosis vaccines clinical trials committee. Br. Med. J. 2 (1959) 379-396
257. MRC. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life: Third report to the Medical Research Council by their tuberculosis vaccines clinical trials committee. Br. Med. J. 1 (1963) 973-978
258. MRC. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Bull. W.H.O. 46 (1972) 371-385
259. Murray C.J.L. Issues in operational, social, and economic research on tuberculosis. In: Bloom B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C.
260. Murray C.J.L. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull. W.H.O. 72 (1994) 429-445
261. Murray C.J.L., DeJonghe E., Chum H.G., NyanguLu D.S., Salomao A., and Styblo K. Cost-effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 338 (1994) 1305-1308
262. Murray C.J.L., Styblo K., and Rouillon A. Tuberculosis in developing countries: Burden, intervention and cost. Bull. Int. Union Against Tuberculosis Lung Dis. 65 (1990) 6-23
263. Murray P.J., Aldovini A., and Young R.A. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc. Natl. Acad. U.S.A. 93 (1996) 934-939
264. Musser J.M., Kapur V., Williams D.L., Kreiswirth B.N., van Soolingen D., and van Embden J.D. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: Restricted array of mutations associated with drug resistance. J. Infect. Dis. 173 (1996) 196-202
265. Myrvik Q.N., Leake E.S., and Wright M.J. Disruption of phagosomal membranes of normal alveolar macrophages by the H37Rv strain of Mycobacterium tuberculosis: A correlate of virulence. Am. Rev. Respir. Dis. 129 (1984) 322-328
266. Newport M.J., Huxley C.M., Huston S., Hawrylowicz C.M., Oostra B.A., Williamson R., and Levin M. A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335 (1996) 1941-1949
267. Nicholson S., da Gloria Bonecini-Almeida M., Lapa e Silva J.R., Nathan C., Xie Q.-W., Mumford R., Weidner J.R., Calaycay J., Geng J., Boechat N., Linhares C., Rom W., and Ho J.L. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J. Exp. Med. 183 (1996) 2293-2302
268. Office of Technology Assessment. "Pharmaceutical R & D: Costs, Risks, and Rewards," (OTA-H-523) (1993), U.S. Government Printing Office, Washington D.C.
269. Opie E.L. Phthisiogenesis and latent tuberculous infection. Am. Rev. Tuberculosis 6 (1922) 525-546
270. Opie E.L. Anatomical characteristics of tuberculosis in Jamaica. Am. Rev. Tuberculosis 22 (1930) 613-625
271. Opie E.L., and Aronson J.D. Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions. Arch. Pathol. 4 (1927) 1-21
272. Pagel W. On the endogenous origin of early pulmonary tuberculosis. The anatomic view of its clinical diagnosis. Am. J. Med. Sci. 189 (1935) 253-270
273. Pal P.G., and Horwitz M.A. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect. Immun. 60 (1992) 4781-4792
274. Pancholi P., Mirza A., Bhardwaj N., and Steinman R.M. Sequestration from immune CD4+ T cells of mycobacteria growing in human macrophages. Science 260 (1993) 984-986
275. Pape J.W., Jean S.S., Ho J.L., Hafner A., and Johnson Jr. W.D. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 342 (1993) 268-272
276. Peizer L.R., Widelock D., and Klein S. Effect of isoniazid on the viability of isoniazid-susceptible and isoniazid-resistant cultures of Mycobacterium tuberculosis. Am. Rev. Tuberculosis 69 (1954) 1022-1028
277. Peizer L.R., Chaves A.D., and Widelock D. The effects of early isoniazid treatment in experimental guinea pig tuberculosis. Am. Rev. Tuberculosis Pulmonary Dis. 76 (1957) 732-751
278. Perriens J.H., St. Louis M.E., Mukadi Y.B., Brown C., Prignot J., Pouthier F., Portaels F., Williame J.-C., Mandala J.K., Kaboto M., Ryder R.W., Roscigno G., and Piot P. Pulmonary tuberculosis in HIV-infected patients in Zaire: A controlled trial of treatment for either 6 or 12 months. N. Engl. J. Med. 332 (1995) 779-784
279. Pfuetze K.H., Pyle M.M., Hinshaw H.C., and Feldman W.H. The first clinical trial of streptomycin in human tuberculosis. Am. Rev. Tuberculosis Pulmonary Dis. 71 (1955) 752-754
280. Pierce C., Dubos R.J., and Middlebrook G. Infection of mice with mammalian tubercle bacilli grown in Tween-albumin liquid medium. J. Exp. Med. 86 (1947) 159-174
281. Pinner M., and Kasper J.A. Pathological peculiarities of tuberculosis in the American negro. Am. Rev. Tuberculosis 26 (1932) 463-491
282. Poccia F., Boullier S., Lecoeur H., Cochet M., Poquet Y., Colizzi V., Fournie J.J., and Gougeon M. Peripheral Vγ9/Vδ2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons. J. Immunol. 157 (1996) 449-461
283. - T lymphocytes to a microbial antigen. Nature (London) 360 (1992) 593-597
284. Quetel C. "History of Syphilis." (1992), Johns Hopkins Univ. Press, Baltimore
285. Rasmussen K.N. The apical localization of pulmonary tuberculosis. Acta Tubercuoea Scand. 34 (1957) 245-259
286. Ratledge C. Nutrition, growth and metabolism. In: Ratledge C., and Stanford J. (Eds). "The Biology of the Mycobacteria, Volume I: Physiology, Identification and Classification" (1982), Academic Press, London 185-271
287. Raviglione M.C., Narain J.P., and Kochi A. HIV-associated tuberculosis in developing countries: Clinical features, diagnosis, and treatment. Bull. W.H.O. 70 (1992) 515-526
288. Raviglione M.C., Sudre P., Rieder H.L., Spinaci S., and Kochi A. Secular trends of tuberculosis in Western Europe. Bull. W.H.O. 71 (1993) 297-306
289. Raviglione M.C., Snider D.E., and Kochi A. Global epidemiology of tuberculosis: Morbidity and mortality of a worldwide epidemic. J. Am. Med. Assoc. 273 (1995) 220-226
290. Rees R.J.W., and D′Arcy Hart P. Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. Br. J. Exp. Patbol. 42 (1961) 83-88
291. Reichle H.S., and Gallavan M. Reactivation of a primary tuberculous complex as a source of tuberculous reinfection. Arch. Pathol. 24 (1937) 201-214
292. Reyrat J.-M., Berthet F.-X., and Gicquel B. The urease locus of Mycobacterium tuberculosis and its utilization for the demonstration of allelic exchange in Mycobacterium bovis bacillus Calmette-Guerin. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 8768-8772
293. Rhines C. The persistence of avian tubercle bacilli in soil and in association with soil micro-organisms. J. Bacteriol. 29 (1935) 299-311
294. Rhodes R. "The Making of the Atomic Bomb." (1986), Simon & Schuster, Inc., New York
295. Rich A.R. "The Pathogenesis of Tuberculosis." (1944), Charles C. Thomas, Springfield, Ilinois
296. Rich A.R., and Follis Jr. R.H. The inhibitory effect of sulfanilamide on the development of experimental tuberculosis in the guinea pig. Bull. Johns Hopkins Hospital 62 (1938) 77-84
297. Rich A.R., and Follis Jr. R.H. The effect of low oxygen tension upon the development of experimental tuberculosis. Bull. Johns Hopkins Hospital 71 (1942) 345-363
298. Riley R.L. Aerial dissemination of pulmonary tuberculosis. Am. Rev. Tuberculosis Pulmonary Dis. 76 (1957) 931-941
299. Riley R.L. Apical localization of pulmonary tuberculosis. Bull Johns Hopkins Hospital 106 (1960) 232-239
300. Riley R.L., Mills C.C., Nyka W., Weinstock N., Storey P.B., Sultan L.U., Riley M.C., and Wells W.F. Aerial dissemination of pulmonary tuberculosis: A two-year study of contagion in a tuberculosis ward. Am. J. Hygiene 70 (1959) 185-196
301. Riley R.L., Mills C.C., O′Grady F., Sultan L.U., Wittstadt F., and Shivpuri D.N. Infectiousness of air from a tuberculosis ward. Ultraviolet irradiation of infected air: Comparative infectiousness of different patients. Am. Rev. Respir. Dis. 85 (1962) 511-525
302. Ristow M., Mohlig M., Rifai M., Schatz H., Feldman K., and Pfeiffer A. New isoniazid/ethionamide resistance gene mutation and screening for multidrug-resistant Mycobacterium tuberculosis strains. Lancet 346 (1996) 502-503
303. Roberts A.D., Sonnenberg M.G., Ordway D.J., Furney S.K., Brennan P.J., Belisle J.T., and Orme I.M. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology 85 (1995) 502-508
304. Robertson H.E. The persistence of tuberculous infections. Am. J. Pathol. 9 Suppl. (1933) 711-718
305. Robinson D.S., Ying S., Taylor I.K., Wangoo A., Mitchell D.M., Kay A.B., Hamid Q., and Shaw R.J. Evidence for a Th1-like bronchoalveolar T-cell subset and predominance of interferon-gamma gene activation in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 149 (1994) 989-993
306. Rook G.A.W., and Bloom B.R. Mechanisms of pathogenesis in tuberculosis. In: Bloom B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C. 485-501
307. Rook G.A.W., Steele J., Ainsworth M., and Champion B.R. Activation of macrophages to inhibit proliferation of Mycobacterium tuberculosis: Comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages. Immunology 59 (1986) 333-338
308. 3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 57 (1986) 159-163
309. Rosenthal S.R., Loewinsohn E., Graham M.L., Liveright D., Thorne M.G., and Johnson V. BCG vaccination against tuberculosis in Chicago: A twenty-year study statistically analyzed. Pediatrics 28 (1961) 622-641
310. Rothman S.M. "Living in the Shadow of Death: Tuberculosis and the Social Experience of Illness in American History." (1994), Harper Collins, New York
311. Rothschild H., Friedenwald J.S., and Bernstein C. The relation of allergy to immunity in tuberculosis. Bull. Johns Hopkins Hospital 54 (1934) 232-276
312. Ryan F. "The Forgotten Plague: How the Battle Against Tuberculosis Was Won-and Lost." (1993), Little, Brown & Company, Boston
313. Saha B., Das G., Vohra H., Ganguly N.K., and Mishra G.C. Macrophage -T cell interaction in experimental mycobacterial infection. Selective regulation of co-stimulatory molecules on Mycobacterium-infected macrophages and its implication in the suppression of cell-mediated immune response. Eur. J. Immunol. 24 (1994) 2618-2624
314. Salo W.L., Aufderheide A.C., Buikstra J., and Holcomb T.A. Identification of Mycobacterium tuberculosis DNA in pre-Columbian Peruvian mummy. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 2091-2094
315. Sanchez F.O., Rodriguez J.I., Agudelo G., and Garcia L.F. Immune responsiveness and lymphokine production in patients with tuberculosis and healthy controls. Infect. Immun. 62 (1994) 5673-5678
316. Schatz A., Bugie E., and Waksman S.A. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proc. Soc. Exp. Biol. Med. 55 (1944) 66
317. Schlesinger L.S. Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors. J. Immunol. 150 (1993) 2920-2930
318. Schlesinger L.S., Bellinger-Kawahara C.G., Payne N.R., and Horwitz M.A. Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. J. Immunol. 144 (1990) 2771-2780
319. Schmidt L.H. Some observations on the utility of simian pulmonary tuberculosis in defining the therapeutic potentialities of isoniazid. Am. Rev. Tuberculosis Pulmonary Dis. 74 Suppl. (1956) 138-159
320. Scorpio A., and Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotin-amidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2 (1996) 662-667
321. Segal W. Growth dynamics of in vivo and in vitro grown mycobacterial pathogens. In: Kubica G.P., and Wayne L.G. (Eds). "The Mycobacteria: A Sourcebook" (1984), Dekker, New York 547-573
322. Segal W., and Bloch H. Biochemical differentiation of Mycobacterium tuberculosis grown in vivo and in vitro. J. Bacteriol. 72 (1956) 132-141
323. Selwyn P.A., Hartel D., Lewis V.A., Schoenbaum E.E., Vermund S.H., Klein R.S., Walker A.T., and Friedland G.H. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 320 (1989) 545-550
324. Sever J.L., and Youmans G.P. The relation of oxygen tension to virulence of tubercle bacilli and to acquired resistance in tuberculosis. J. Infect. Dis. 101 (1957) 193-202
325. Sherman D.R., Mdluli K., Hickey M.J., Arain T.M., Morris S.L., Barry III C.E., and Stover C.K. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 272 (1996) 1641-1643
326. Sieling P.A., Chatterjee D., Porcelli S.A., Prigozy T.I., Mazzaccaro R.J., Soriano T., Bloom B.R., Brenne M.B., Kronenberg M., Brennan P.J., and Modlin R.L. CD1-restricted T cell recognition of microbial lipoglycan antigens. Science 269 (1995) 227-230
327. Simonds B. "Tuberculosis in Twins." (1963), Pitman Medical, London
328. Sllifka M.K., and Ahmed R. Long-term humoral immunity against viruses: Revisiting the issue of plasma cell longevity. Trends Microbiol. 4 (1996) 394-400
329. Smida J., Kazda J., and Stackebrandt E. Molecular-genetic evidence for the relationship of Mycobacterium leprae to slow-growing pathogenic mycobacteria. Int. J. of Leprosy 56 (1988) 449-454
330. Smith D.W., Wiegeshaus E.H., and Edwards M.L. In: Bendinelli M., and Friedman H. (Eds). "Mycobacterium tuberculosis: Interactions with the Immune System" (1988), Plenum, New York 341-370
331. Snapper S.B., Lugosi L., Jekkel A., Melton R.E., Kieser T., Bloom B.R., and Jacobs Jr. W.R. Lysogeny and transformation in mycobacteria: Stable expression of foreign genes. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 6987-6991
332. Sonkin L.S. The role of particle size in experimental air-borne infection. Am. J. Hygiene 53 (1951) 337-354
333. Stead W.W. The pathogenesis of pulmonary tuberculosis among older persons. Am. Rev. Respir. Dis. 91 (1965) 811-822
334. Stead W.W. Genetics and resistance to tuberculosis: Could resistance be enhanced by genetic engineering?. Ann. Internal Med. 116 (1992) 937-941
335. Stead W.W., and Lofgren J.P. Does the risk of tuberculosis increase with old age? J. Infect. Dis. 147 (1983) 951-955
336. Stead W.W., Senner J.W., Reddick W.T., and Lofgren J.P. Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N. Engl. J. Med. 322 (1990) 422-427
337. Stead W.W., Eisenach K.D., Cave M.D., Beggs M.L., Templeton G.L., Thoen C.O., and Bates J.H. When did Mycobacterium tuberculosis infection first occur in the New World?. Am. J Respir. Crit. Care Med. 151 (1995) 1267-1268
338. Stenger S., Donhauser N., Thuring H., Rollinghoff M., and Bogdan C. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J. Exp. Med. 183 (1996) 1501-1514
339. Stenger S., Mazzaccaro R.J., Uyemura K., Cho S., Barnes P.F., Rosat J.-P., Sette A., Brenner M.B., Porcelli S.A., Bloom B.R., and Modlin R.L. Differential effects of cytolytic T cell subsets on intracellular infection. Science 276 (1997) 1684-1687
340. Stover C.K., de la Cruz V.F., Fuerst T.R., Burlein J.E., Benson L.A., Bennett L.T., Bansal G.P., Young J.F., Lee M.H., Hatfull G.F., Snapper S.B., Barletta R.G., Jacobs Jr. W.R., and Bloom B.R. New Use of BCG for recombinant vaccines. Nature (London) 351 (1991) 456-460
341. Stover C.K., Bansal G.P., Hanson M.S., Burlein J.E., Palaszynski S.R., Young J.F., Koenig S., Young D.B., Sadziene A., and Barbour A.G. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: A candidate Lyme disease vaccine. J. Exp. Med. 178 (1993) 197-209
342. Sturgill-Koszycki S., Schlesinger P.H., Chakraborty P., Haddiz P.L., Collins H.L., Fok A.K., Allen R.D., Gluck S.L., Heuser J., and Russell D.G. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 263 (1994) 678-681
343. Styblo K. Epidemiology of tuberculosis. Selected Papers of the Royal Netherlands Tuberculosis Association 24 (1991) 1-136
344. Sultan L., Nyka W., Mills C., O′Grady F., Wells W., and Riley R.L. Tuberculosis disseminators: A study of the variability of aerial infectivity of tuberculous patients. Am. Rev. Respir. Dis. 82 (1960) 358-369
345. Survel H.-M., Troye-Blomberg M., Paulie S., Andersson G., Moreno C., Pasvol G., and Ivanyi J. Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 81 (1994) 171-176
346. Sutherland I., and Lindgren I. The protective effect of BCG vaccination as indicated by autopsy studies. Tubercle 60 (1979) 225-231
347. Sweany H.C., Cook C.E., and Kegerreis R. A study of the position of primary cavities in pulmonary tuberculosis. Am. Rev. Tuberculosis 24 (1931) 558-582
348. Takiff H.E., Salazar L., Guerrero C., Philipp W., Huang W.H., Kreisworth B., Cole S.T., Jacobs Jr. W.R., and Telenti A. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Cbemotber. 38 (1994) 773-780
349. Tanaka Y., Morita C.T., Tanaka Y., Nieves E., Brenner M.B., and Bloom B.R. Natural and synthetic non-peptide antigens recognized by human γ/δ T cells. Nature 375 (1995) 155-158
350. Tascon R.E., Colston M.J., Ragno S., Stavropoulos E., Gregory D., and Lowrie D.B. Vaccination against tuberculosis by DNA injection. Nat. Med. 2 (1996) 888-892
351. Telenti A., Imboden P., Marchesi F., Lowrie D., Cole S.T., Colston M.J., Matter L., Schoolfer K., and Bodmer T. Detection of rifampicin-resistant mutations in Mycobacterium tuberculosis. Lancet 341 (1993) 647-650
352. Telenti A., Philipp W., Sreevatsan S., Bernasconi C., Stockbauer K.E., Wieles B., Musser J.M., and Jacobs Jr. W.R. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat. Med. 3 (1997) 567-570
353. Thomas T. Survey: Sub-Saharan Africa. The Economist 340 Issue 7982 (1996) September 7-13
354. Toossi Z., Gogate P., Shiratsuchi H., Young T., and Ellner J.J. Enhanced production of TGF-β by blood monocytes from patients with active tuberculosis and presence of TGF-β in tuberculous granulomatous lung lesions. J. Immunol. 154 (1995) 465-473
355. Toossi Z., Young T.-G., Averill L.E., Hamilton B.D., Shiratsuchi H., and Ellner J.J. Induction of transforming growth factor β1 by purified protein derivative of Mycobacterium tuberculosis. Infect. Immun. 63 (1995) 224-228
356. Trudeau E.L. "An Autobiography." (1916), Doubleday Page & Co., Garden City, New York
357. Tsukaguchi K., Balaji K.N., and Boom W.H. CD4+ αβ T cell and γδ T cell responses to Mycobacterium tuberculosis. J. Immunol. 154 (1995) 1786-1796
358. Tsunawaki S., Sporn M., Ding A., and Nathan C. Deactivation of macrophages by TGF-β. Nature (London) 334 (1988) 260-264
359. Tuberculosis Prevention Trial, Madras. Trial of BCG vaccines in south India for tuberculosis prevention. Indian J. Med. Res. 72 Suppl. (1980) 1-74
360. Turner J., and Dockrell H.M. Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8+ T cells in vitro. Immunology 87 (1996) 339-342
361. Ueta C., Tsuyuguchi I., Kawasumi H., Takashima T., Toba H., and Kishimoto S. Increase of γδ T cells in hospital workers who are in close contact with tuberculosis patients. Infect. Immun. 62 (1994) 5434-5441
362. Vandiviere H.M., Loring W.E., Melvin I., and Willis S. The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection. Am. J. Med. Sci. 232 (1956) 30-37
363. Vandiviere H.M., Dworski M., Melvin I.G., Watsonk A.K., and Begley J. Efficacy of Bacillus Calmette-Guerin and isoniazid-resistant Bacillus Calmette-Guerin with and without isoniazid chemoprophylaxis from day of vaccination. II. Field trial in man. Am. Rev. Respir. Dis. 108 (1973) 301-313
364. Vidal S.M., Malo D., Vogan K., Skamene E., and Gros P. Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. Cell 73 (1993) 469-485
365. von Reyn C.F., Clements C.J., and Mann J.M. Human immunodeficiency virus infection and routine childhood immunisation. Lancet 2 (1987) 669-672
366. Vordermeier H.M., Venkataprasad N., Harris D.P., and Ivanyi J. Increase of tuberculous infection in the organs of B cell-deficient mice. Clin. Exp. Immunol. 106 (1996) 312-316
367. Waksman S.A. "The Conquest of Tuberculosis." (1964), Robert Hale Limited, London
368. Wallace J.G. The heat resistance of tubercle bacilli in the lungs of infected mice. Am. Rev. Respir. Dis. 83 (1961) 866-871
369. Wallace M., Scharko A.M., Pauza C.D., Fisch P., Imaoka K., Kawabata S., Fujihashi K., Kiyono H., Tanaka Y., Bloom B.R., and Malkovsky M. Functional γδT-lymphocyte defect associated with human immunodeficiency virus infections. Mol. Med. 3 (1997) 60-71
370. Wang C.Y. Latent tuberculosis. Lancet 2 (1916) 417-419
371. Wayne L.G., and Salkin D. The bacteriology of resected tuberculous pulmonary lesions. I. The effect of interval between reversal of infectiousness and subsequent surgery. Am. Rev. Tuberculosis Pulmonary Dis. 74 (1956) 376-387
372. Wayne L.G. Synchronized replication of Mycobacterium tuberculosis. Infect. Immun. 17 (1977) 528-530
373. Wayne L.G. Cultivation of Mycobacterium tuberculosis for research purposes. In: Bloom B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C. 73-83
374. Wayne L.G., and Hayes L.G. An in vitro model for sequential analysis of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64 (1996) 2062-2069
375. Wayne L.G., and Sramek H.A. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38 (1994) 2054-2058
376. Weigel B.J. Intrapulmonary cavitation in tuberculosis: A clinical, laboratory and X-ray study of 125 patients. Am. Rev. Tuberculosis 10 (1924) 319-328
377. Weis S.E., Slocum P.C., Blais F.X., King B., Nunn M., Matney G.B., Gomez E., and Foresman B.H. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N. Engl. J. Med 330 (1994) 1179-1184
378. Weltman A.C., and Rose D.N. The safety of Bacille Calmette-Guerin vaccination in HIV infection and AIDS. AIDS 7 (1993) 149-157
379. Weshch D., Kabelitz D., Friese K., and Pechhold K. Mycobacteria-reactive γδ T cells in HIV-infected individuals: Lack of V γ9 cell responsiveness is due to deficiency of antigen-specific CD4 helper type 1 cells. Eur. J. Immunol. 26 (1996) 557-562
380. West J.B. "Regional Differences in the Lung." (1977), Academic Press, New York
381. West J.B. "Respiratory Physiology--The Essentials,". 5th Ed. (1995), Williams & Wilkins, Baltimore
382. Whalen C., Horsburgh C.R., Hom D., LaHart C., Simberkoff M., and Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am. J. Respir. Crit. Care Med. 151 (1995) 129-135
383. Wheeler P.R., and Ratledge C. Use of carbon sources for lipid biosynthesis in Mycobacterium leprae: A comparison with other pathogenic mycobacteria. J. Gen. Microbiol. 134 (1988) 2111-2121
384. Wheeler P.R., and Ratledge C. Metabolism of Mycobacterium tuberculosis. In: Bloom B.R. (Ed). "Tuberculosis: Pathogenesis, Protection, and Control" (1994), ASM Press, Washington D.C. 353-385
385. Williams D.L., Waguespack C., Eisenach K., Crawford J.T., Portaels F., Salfinger M., Nolan C.M., Abe C., Sticht-Groh V., and Gillis T.P. Characterization of rifampin resistance in pathogenic mycobacteria. Antimicrob. Agents Chemother. 38 (1994) 2380-2386
386. Wilson M.E., Fineberg H.V., and Colditz G.A. Geographic latitude and the efficacy of bacillus Calmette-Guerin vaccine. Clin. Infect. Dis. 20 (1995) 982-991
387. Wilson T.M., and Collins D.M. ahpC a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Mol. Microbiol. 19 (1996) 1025-1034
388. Wilson T.M., de Lisle G.W., and Collins D.M. Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol. Microbiol. 15 (1995) 1009-1015
389. World Bank. "Investing in Health: World Development Report 1993." (1993), Oxford Univ. Press, New York
390. World Health Organization. Tuberculosis control and research strategies for the 1990s: memorandum from a WHO meeting. Bull. W.H.O. 70 (1992) 17-21
391. World Health Organization. "Groups at Risk: WHO Report on the Tuberculosis Epidemic, 1996." (1996), World Health Organization, Geneva
392. Wright S., and Lewis P.A. Factors in the resistance of guinea pigs to tuberculosis, with especial regard to inbreeding and heredity. Am. Nat. 55 (1921) 20-50
393. Xu S., Cooper A., Sturgill-Koszycki S., van Heyningen T., Chatterjee D., Orme I., Allen P., and Russell D.G. Intracellular trafficking in Mycobacterium tuberculosis and Mycobacterium avium-infected macrophages. J. Immunol. 153 (1994) 2568-2578
394. Yamamura Y., Ogawa Y., Maeda H., and Yamamura Y. Prevention of tuberculous cavity formation by desensitization with tuberculin-active peptide. Am. Rev. Respir. Dis. 109 (1974) 594-601
395. Yegian D., and Vanderlinde R.J. The resistance of tubercle bacilli to chemotherapeutic agents. Am. Rev. Tuberculosis 61 (1950) 483-507
396. Yuan Y., Crane D.D., and Barry III C.E. Stationary phase-associated protein expression in Mycobacterium tuberculosis: Function of the mycobacterial α-crystallin homolog. J. Bacteriol. 178 (1996) 4484-4492
397. Zhang Y., and Young D.B. Molecular mechanisms of isoniazid: A drug at the front line of tuberculosis control. Trends Microbiol. 1 (1993) 109-113
398. Zhang Y., Heym B., Allen B., Young D., and Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature (London) 358 (1992) 591-593
399. Zhang M., Gately M.K., Wang E., Gong J., Wolf S.F., Lu S., Modlin R.L., and Barnes P.F. Interleukin 12 at the site of disease in tuberculosis. J. Clin. Invest. 93 (1994) 1733-1739
400. Zhang M., Lin Y., Iyer D.V., Gong J., Abrams J.S., and Barnes P.F. T-cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect. Immun. 63 (1995) 3231-3234